Mylan has renewed calls for a temporary injunction against Sun Pharma pending an appeal of a ruling invalidating its patents for Lipidil, and has sued a second generic drug maker, Cipla, over the cholesterol-lowering medication.
A senior female partner at Piper Alderman will go into mediation this week with representatives of the firm’s partnership to try to resolve her sex discrimination lawsuit, which alleges a group of equity partners have used baseless complaints of bullying to try to push her out.
A leading female partner at Piper Alderman, who is suing the firm’s other partners for sex discrimination, has told a court their attempt to oust her from the partnership was based on groundless claims of bullying and was a case of “skulduggery”.
Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.
Mylan has appealed a ruling invaliding claims of its cholesterol drug patent and dismissing its patent infringement case against Sun Pharma.
Generic drug maker Sun Pharma has emerged victorious in a lawsuit brought against it by Mylan relating to Sun’s plans to launch a generic version of cholesterol drug fenofibrate.
Medical device maker B. Braun Melsungen is appealing a ruling that invalidated its intravenous catheter patents and dismissed allegations of infringement against rival Becton Dickinson.
Keyboard specialist PKT Technologies has returned for an encore in a six-year long trade mark dispute, appealing a $384,000 judgment against it for violating a trade mark licence agreement with engineer Peter Vogel, inventor of the groundbreaking synthesiser behind some of 80s pop music’s most iconic sounds.
A court has delivered a loss for Germany-based B. Braun Melsungen, dismissing its allegations that US-based device manufacturer Becton Dickinson infringed three of its intravenous catheter patents and ruling the patents invalid.
Drug maker Neurim Pharmaceuticals is battling to amend its Australian patent for the blockbuster sleeping pill Circadin over opposition from two generic pharmaceutical companies, which have accused Neurim of attempting to gain an unfair advantage by delaying the amendment bid until now.